Hantavirus Outbreak on Cruise Ship Highlights Lack of Treatments and Vaccines

An outbreak of the Andean strain of hantavirus aboard the cruise ship Hondius has raised urgent questions about the lack of specific treatments and vaccines for this deadly virus. Currently, no targeted therapy exists for this strain, which is unique in its ability to transmit between humans and carries an estimated lethality rate of 40%. A French passenger from the cruise is currently in serious condition at Bichat Hospital in Paris. Historically, hantavirus has been a neglected tropical disease, primarily affecting South American countries like Chile and Argentina with 50 to 100 annual cases transmitted via rodent excretions. The low number of patients has hindered clinical trials and funding, similar to other neglected diseases like sleeping sickness. However, this epidemic outbreak and rising case numbers in Argentina may shift public health priorities, potentially boosting research and development efforts. Scientists at the Malbran Institute in Buenos Aires are actively studying the virus, but significant challenges remain in developing effective medical countermeasures due to limited historical investment and small patient pools for testing.